Education
About Us
Working with TipRanks
Follow Us
Cassava Sciences (SAVA)
NASDAQ:SAVA
SAVA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.23 - $42.20
Previous CloseN/A
Volume2.36M
Average Volume (3M)1.50M
Market Cap
$135.26M
Enterprise Value$1.22B
Total Cash (Recent Filing)$128.57M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta>-0.01
Next Earnings
May 08, 2025EPS Estimate
-0.58Last Dividend Ex-Date
Dec 13, 2012Dividend YieldN/A
Share Statistics
EPS (TTM)-1.45
Shares Outstanding48,307,896
10 Day Avg. Volume1,169,718
30 Day Avg. Volume1,496,068
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market Cap9.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-8.60
Forecast
1Y Price Target
$20.00Price Target Upside614.29% Upside
Rating ConsensusHold
Number of Analyst Covering1
---
Bulls Say, Bears Say
Bulls Say
Biomarker ResultsBiomarker results are expected to be key to interpreting simufilam's performance, with changes in biomarker levels directionally supporting simufilam’s positive effect and mechanism of action.
Cash ReservesCassava Sciences has sufficient cash reserves operationally through 2026 despite the trial setbacks.
Licensing AgreementThe company’s licensing of rights from Yale to an issued patent to use of simufilam as a potential treatment for seizures related to rare neurodevelopment disorders is seen as a positive development.
Bears Say
Clinical Trial SetbacksSimufilam failed to show a significant reduction in cognitive or functional decline versus placebo in mild-to-moderate Alzheimer’s disease patients.
Stock Rating DowngradeAnalyst downgrades the stock rating to Neutral from Buy, removing forecasts for simufilam approval and related revenues.
Trial FailureTop-line results from ReThink-ALZ, a Phase 3 clinical trial with simufilam in patients with mild-to-moderate Alzheimer's disease, did not meet the study’s pre-specified co-primary, secondary, and exploratory biomarker endpoints, leading to the trial's termination.
---
Ownership Overview
7.59% Insiders
7.78% Mutual Funds
11.57% Other Institutional Investors
66.60% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SAVA FAQ
What was Cassava Sciences’s price range in the past 12 months?
Cassava Sciences lowest stock price was $2.23 and its highest was $42.20 in the past 12 months.
What is Cassava Sciences’s market cap?
Cassava Sciences’s market cap is $135.26M.
When is Cassava Sciences’s upcoming earnings report date?
Cassava Sciences’s upcoming earnings report date is May 08, 2025 which is in 43 days.
How were Cassava Sciences’s earnings last quarter?
Cassava Sciences released its earnings results on Mar 03, 2025. The company reported -$0.57 earnings per share for the quarter, beating the consensus estimate of -$0.583 by $0.013.
Is Cassava Sciences overvalued?
According to Wall Street analysts Cassava Sciences’s price is currently Undervalued.
Does Cassava Sciences pay dividends?
Cassava Sciences pays a Notavailable dividend of $5.25 which represents an annual dividend yield of N/A. See more information on Cassava Sciences dividends here
What is Cassava Sciences’s EPS estimate?
Cassava Sciences’s EPS estimate is -0.58.
How many shares outstanding does Cassava Sciences have?
Cassava Sciences has 48,307,896 shares outstanding.
What happened to Cassava Sciences’s price movement after its last earnings report?
Cassava Sciences reported an EPS of -$0.57 in its last earnings report, beating expectations of -$0.583. Following the earnings report the stock price went up 3.333%.
Which hedge fund is a major shareholder of Cassava Sciences?
Currently, no hedge funds are holding shares in SAVA
---
Cassava Sciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$20.00 (614.29% Upside)
$20.00 (614.29% Upside)
Blogger Sentiment
Bearish
SAVA Sentiment 89%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 427.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $253.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 10.0%
Last 30 Days ▼ 10.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-85.86%
12-Months-Change
Fundamentals
Return on Equity
-17.19%
Trailing 12-Months
Asset Growth
3.87%
Trailing 12-Months
Company Description
Cassava Sciences
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
---
SAVA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of promising progress in clinical trials and financial stability, but also highlighted increased administrative costs and legal challenges. The anticipation of Phase III trial results is a critical point of focus.Read More>---
SAVA Stock 12 Month Forecast
Average Price Target
$20.00
▲(614.29% Upside)
Technical Analysis
Best Analysts Covering SAVA
1 Year
1 Year Success Rate
1/3 ratings generated profit
1 Year Average Return
-42.20%
reiterated a sell rating yesterday
Copying Elemer Piros's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -42.20% per trade.
---